During the last three months, 13 analysts shared their evaluations of Amgen (NASDAQ:AMGN), revealing diverse outlooks from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Amgen and provided 12-month price targets. The average target is $340.38, accompanied by a high estimate of $405.00 and a low estimate of $215.00. This upward trend is evident, with the current average reflecting a 0.18% increase from the previous average price target of $339.78.

Exploring Analyst Ratings: An In-Depth Overview

The standing of Amgen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Amgen's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Amgen analyst ratings.

Get to Know Amgen Better

Financial Insights: Amgen

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Positive Revenue Trend: Examining Amgen's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.18% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 33.28%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Amgen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 42.08% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.11%, the company showcases effective utilization of assets.

Debt Management: Amgen's debt-to-equity ratio stands notably higher than the industry average, reaching 8.02. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

Analyst Ratings: Simplified

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.